Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

Shih Hsin Tu, Chih Chiang Chang, Ching Shyang Chen, Ka Wai Tam, Ying Jan Wang, Chia Hwa Lee, Hsiao Wei Lin, Tzu Chun Cheng, Ching Shui Huang, Jan Show Chu, Neng Yao Shih, Li Ching Chen, Sy Jye Leu, Yuan Soon Ho, Chih Hsiung Wu

研究成果: 雜誌貢獻文章

59 引文 (Scopus)

摘要

Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P
原文英語
頁(從 - 到)539-553
頁數15
期刊Breast Cancer Research and Treatment
121
發行號3
DOIs
出版狀態已發佈 - 六月 2010

指紋

Phosphopyruvate Hydratase
Tamoxifen
Breast Neoplasms
Neoplasms
Messenger RNA
Estrogen Receptors
Real-Time Polymerase Chain Reaction
Lung Neoplasms
Lasers
Enzymes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells. / Tu, Shih Hsin; Chang, Chih Chiang; Chen, Ching Shyang; Tam, Ka Wai; Wang, Ying Jan; Lee, Chia Hwa; Lin, Hsiao Wei; Cheng, Tzu Chun; Huang, Ching Shui; Chu, Jan Show; Shih, Neng Yao; Chen, Li Ching; Leu, Sy Jye; Ho, Yuan Soon; Wu, Chih Hsiung.

於: Breast Cancer Research and Treatment, 卷 121, 編號 3, 06.2010, p. 539-553.

研究成果: 雜誌貢獻文章

Tu, Shih Hsin ; Chang, Chih Chiang ; Chen, Ching Shyang ; Tam, Ka Wai ; Wang, Ying Jan ; Lee, Chia Hwa ; Lin, Hsiao Wei ; Cheng, Tzu Chun ; Huang, Ching Shui ; Chu, Jan Show ; Shih, Neng Yao ; Chen, Li Ching ; Leu, Sy Jye ; Ho, Yuan Soon ; Wu, Chih Hsiung. / Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells. 於: Breast Cancer Research and Treatment. 2010 ; 卷 121, 編號 3. 頁 539-553.
@article{a0a9c9dcd0874f329c963e3821bedbf7,
title = "Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells",
abstract = "Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P",
keywords = "Breast cancer, Enolase-1, Estrogen receptor alpha, Nuclear factor kappa B, Tamoxifen",
author = "Tu, {Shih Hsin} and Chang, {Chih Chiang} and Chen, {Ching Shyang} and Tam, {Ka Wai} and Wang, {Ying Jan} and Lee, {Chia Hwa} and Lin, {Hsiao Wei} and Cheng, {Tzu Chun} and Huang, {Ching Shui} and Chu, {Jan Show} and Shih, {Neng Yao} and Chen, {Li Ching} and Leu, {Sy Jye} and Ho, {Yuan Soon} and Wu, {Chih Hsiung}",
year = "2010",
month = "6",
doi = "10.1007/s10549-009-0492-0",
language = "English",
volume = "121",
pages = "539--553",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

AU - Tu, Shih Hsin

AU - Chang, Chih Chiang

AU - Chen, Ching Shyang

AU - Tam, Ka Wai

AU - Wang, Ying Jan

AU - Lee, Chia Hwa

AU - Lin, Hsiao Wei

AU - Cheng, Tzu Chun

AU - Huang, Ching Shui

AU - Chu, Jan Show

AU - Shih, Neng Yao

AU - Chen, Li Ching

AU - Leu, Sy Jye

AU - Ho, Yuan Soon

AU - Wu, Chih Hsiung

PY - 2010/6

Y1 - 2010/6

N2 - Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P

AB - Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P

KW - Breast cancer

KW - Enolase-1

KW - Estrogen receptor alpha

KW - Nuclear factor kappa B

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=77953122846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953122846&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0492-0

DO - 10.1007/s10549-009-0492-0

M3 - Article

VL - 121

SP - 539

EP - 553

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -